Evidence map›Paper›PMID 41793622›Full record

Trial reportJournal of patient-reported outcomes2026

Validation of PREM-PS, a patient-reported experience instrument, in a randomized controlled trial of pregnant women undergoing prenatal screening.

Alix Dubeau, Meryeme El Balqui, Denis Talbot, François Rousseau, Sylvie Langlois, Weihong Chen, François Audibert, Emmanuel Bujold, Jean-Claude Forest, Suélène Georgina Dofara and 1 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyValidation Study
In one paragraph

Trial report in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03831256 (PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03831256 naactive not recruitingnot on this map

PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood : Towards First Tier Screening and Beyond

TypeinterventionalSponsorCHU de Quebec-Universite LavalRan2020 to 2025Enrolled7,849ConditionsPrenatal Disorder, AneuploidyArmsTraditional integrated prenatal screening, Second-tier Non-invasive prenatal screening (NIPS), First-tier Non-invasive prenatal screening (NIPS), Invasive prenatal testing for fetal aneuploidy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alix DubeauDépartement de mathématiques et de statistique, Université Laval, Québec, QC, Canada. a.dubeau2@gmail.com.ORCID http://orcid.org/0009-0009-2323-8760
Meryeme El BalquiVITAM - Centre de recherche en santé durable, Centre intégré universitaire de santé et services sociaux (CIUSSS) de la Capitale- Nationale; Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0009-0007-1665-725X
Denis TalbotDépartement de médecine sociale et préventive, Faculté de médecine, Québec, Canada.ORCID http://orcid.org/0000-0003-0431-3314
François RousseauAxe santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-4504-5507
Sylvie LangloisDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-9301-3625
Weihong ChenDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
François AudibertCentre de recherche du CHU Ste-Justine - Université de Montréal; Département de Gynécologie-Obstétrique, Université de Montréal, Montréal, QC, Canada.ORCID http://orcid.org/0000-0002-2697-3826
Emmanuel BujoldAxe Reproduction, santé de la mère et de l'enfant, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-6936-4369
Jean-Claude ForestDépartement de biologie moléculaire, de biochimie médicale et de pathologie, Faculté de médecine, Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-5910-5822
Suélène Georgina DofaraVITAM - Centre de recherche en santé durable, Centre intégré universitaire de santé et services sociaux (CIUSSS) de la Capitale- Nationale; Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0009-0008-0537-8965
France LégaréVITAM - Centre de recherche en santé durable, Centre intégré universitaire de santé et services sociaux (CIUSSS) de la Capitale- Nationale; Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-2296-6696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatient-reported experience measures are valuable instruments for assessing care quality in alignment with the Triple Aim framework. We sought to validate the PREM-PS questionnaire (Patient Reported Experience Measure – Prenatal Screening) by evaluating its psychometric properties (structural validity, internal consistency, and cross-cultural validity) for Canadian French-and English-speaking populations. METHODOLOGY: This secondary analysis used data from a prospective, open-label, multicenter randomized trial in Quebec and British Columbia (2019–2023). Pregnant women aged 19+ were randomized 2:1 to receive either first-tier cell-free DNA (cfDNA) or traditional biochemical screening for chromosomal anomalies (T21, T18, T13). Participants completed the PREM-PS, a 10-item questionnaire on a 5-point Likert scale, at 22 weeks of pregnancy. Exploratory factor analysis, conducted separately for French and English questionnaires, used half the data to identify underlying factors. Confirmatory factor analysis of the remaining data evaluated structural validity. Internal consistency was assessed using Cronbach’s alpha, and cross-cultural validity through measurement invariance analyses. Mean scores were compared across arms using linear mixed models.

resultsOf 7815 enrolled pregnant women, 3398 completed the French questionnaire and 2875 the English version (80.3% response rate, 96.4% completion rate). Mean age was 32.11 years (SD = 4.01), with 65.1% identifying as White. Factor analyses retained seven items grouped into two latent factors interpreted as Communication and Professionalism. Standardized loadings from exploratory factor analysis ranged from 0.66–0.93 (French) and 0.69–0.96 (English), while standardized parameter estimates from the confirmatory factor analysis ranged from 0.67–0.98 (French) and 0.62–0.98 (English). Cronbach’s alpha exceeded 0.85 for both factors in French and 0.88 in English. No significant differences were observed between the two study arms for either Professionalism or Communication scores, indicating comparable patient-reported experiences regardless of screening method.

conclusionThe PREM-PS demonstrates adequate validity for assessing patient-reported experiences of pregnant women undergoing prenatal screening in both Canadian French and English, with potential to guide improvements in prenatal care.

trial registrationClinicalTrials.gov, NCT03831256. Registered February 5th, 2019, https://clinicaltrials.gov/study/NCT03831256?term=NCT03831256&rank=1

Indexed as

Patient Reported Outcome MeasuresPregnant PeoplePrenatal DiagnosisAdultBritish ColumbiaFemaleHumansPregnancyProspective StudiesPsychometricsQuebecReproducibility of ResultsSurveys and QuestionnairesCross-cultural validityFactor analysisFirst-tier cfDNA prenatal screeningInternal consistencyPatient-reported experience measures (PREMs)Prenatal screeningPsychometric validationStructural validity

Identifiers

PMID41793622
PMCPMC13079255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.